title: [Seroprevalence of varicella-zoster virus antibodies after the recent introduction of the universal childhood immunisation schedule in the Community of Madrid].
abstract: OBJECTIVE
  In November 2006, the Community of Madrid included the chickenpox vaccine into the immunisation schedule for children from 15 months of age. This was withdrawn in January 2014. Seroprevalence of antibodies to the virus is estimated after the first 2-3 years from the inclusion of the vaccine, and as well as its evolution since 1999.
  
  
  METHODS
  A cross-sectional study was conducted on the target population consisting of residents in the Community of Madrid between 2 and 60 years of age. Measurement of IgG antibodies was performed using an ELISA technique. Seroprevalence was estimated according to sociodemographic characteristics using multiple logistic regressions. The results are compared with previous surveys. Also, the seroprevalence and geometric mean of the antibody according immunisation status and history of the disease are presented. The confidence level used is 95%.
  
  
  RESULTS
  A total of 4,378 subjects were included, with a response rate of 69%. The estimated seroprevalence was 95.3% (95% CI: 94.6% - 95.9%). Over 90% of children from the age of 10 have antibodies. The seroprevalence was higher in people with less education. The seroprevalence of immunity vaccine exceeds 90% in the first year after vaccination, but in the second year decreased to 82.6% (95% CI 56.0 - 94.7). Significant differences, attributable to universal vaccination, were found compared to previous surveys.
  
  
  CONCLUSIONS
  Continued surveillance is needed in order to assess the impact of the withdrawal of the recommendation to vaccinate at 15 months.
authors: Dirección General de Salud Pública, Consejería de Sanidad, Comunidad de Madrid, Madrid, España. Electronic address: luis.garcia@salud.madrid.org.
authors: Luis
authors: L
authors: García-Comas
authors: Dirección General de Salud Pública, Consejería de Sanidad, Comunidad de Madrid, Madrid, España.
authors: María
authors: M
authors: Ordobás Gavín
authors: Dirección General de Salud Pública, Consejería de Sanidad, Comunidad de Madrid, Madrid, España.
authors: Juan Carlos
authors: JC
authors: Sanz Moreno
authors: Dirección General de Salud Pública, Consejería de Sanidad, Comunidad de Madrid, Madrid, España.
authors: Belén
authors: B
authors: Ramos Blázquez
authors: Dirección General de Salud Pública, Consejería de Sanidad, Comunidad de Madrid, Madrid, España.
authors: M Angeles
authors: MA
authors: Gutiérrez Rodríguez
authors: Dirección General de Salud Pública, Consejería de Sanidad, Comunidad de Madrid, Madrid, España.
authors: Dolores
authors: D
authors: Barranco Ordóñez
mesh_terms: D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D019433:Chickenpox Vaccine / Q000008:administration & dosage / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D014645:Herpesvirus 3, Human / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D008875:Middle Aged; D016036:Seroepidemiologic Studies
chemical_list: D000914:Antibodies, Viral; D019433:Chickenpox Vaccine
keywords: Chickenpox; Estudios seroepidemiológicos; Public health surveillance; Sero-epidemiological studies; Varicela; Vigilancia de salud pública